Princeton, New Jersey-based Bristol-Myers Squibb Company (BMY) discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. With a market cap of $120.8 billion, the company offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. BMY is expected to release its Q3 2026 earnings before the market opens on Thursday, October 29.
Ahead of this event, analysts anticipate the company will generate earnings of $1.48 per share, representing a decrease of 9.2% from $1.63 per share reported in the same quarter last year. The company has surpassed the Street’s bottom-line estimates in each of the past four quarters, which is impressive.